• Amgen's Osteoporosis Drug Wins European Nod, With a Heart Warning

    1 month ago - By Xconomy

    An osteoporosis drug developed by Amgen now has marketing approval in Europe, but it carries a warning that the medicine can raise the risk of cardiovascular problems. Romosozumab treats postmenopausal woman who have osteoporosis, a disease that weakens bones, making them susceptible to fracture. The antibody drug, given as a once monthly injection, was developed to block sclerostin, a protein involved in the signaling pathway that regulates bone growth. The drug is intended to provide a dual effect: It increases bone formation and reduces bone loss in patients who have the disease, which...
    Read more ...